BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ferone D, Semino C, Boschetti M, Cascini GL, Minuto F, Lastoria S. Initial Staging of Lymphoma With Octreotide and Other Receptor Imaging Agents. Seminars in Nuclear Medicine 2005;35:176-85. [DOI: 10.1053/j.semnuclmed.2005.03.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Priyadarshini S, Allison DB, Chauhan A. Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review. Pharmaceutics 2022;14:1394. [DOI: 10.3390/pharmaceutics14071394] [Reference Citation Analysis]
2 Juntikka T, Vaittinen S, Vahlberg T, Jyrkkiö S, Minn H. Somatostatin Receptors and Chemokine Receptor CXCR4 in Lymphomas: A Histopathological Review of Six Lymphoma Subtypes. Front Oncol 2021;11:710900. [PMID: 34307181 DOI: 10.3389/fonc.2021.710900] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Чернов В, Chernov V, Дудникова Е, Dudnikova E, Гольдберг В, Goldberg V, Кравчук Т, Kravchuk T, Данилова А, Danilova A, Зельчан Р, Zel'chan R, Медведева А, Medvedeva A, Синилкин И, Sinilkin I, Брагина О, Bragina O, Белевич Ю, Belevich Y, Королева Е, Koroleva E. Single-Photon Emission Computerized Tomography in the Diagnosis and Monitoring of Lymphomas. Medical Radiology and radiation safety 2019. [DOI: 10.12737/article_5cf3dfefe60b13.90120976] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Bhanat E, Koch CA, Parmar R, Garla V, Vijayakumar V. Somatostatin receptor expression in non-classical locations – clinical relevance? Rev Endocr Metab Disord 2018;19:123-32. [DOI: 10.1007/s11154-018-9470-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
5 Ruuska T, Ramírez Escalante Y, Vaittinen S, Gardberg M, Kiviniemi A, Marjamäki P, Kemppainen J, Jyrkkiö S, Minn H. Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at 68Ga-DOTANOC PET/CT imaging. Acta Oncol 2018;57:283-9. [PMID: 28686510 DOI: 10.1080/0284186X.2017.1342864] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
6 Yamaga LYI, Wagner J, Funari MBDG. 68Ga-DOTATATE PET/CT in Nonneuroendocrine Tumors: A Pictorial Essay. Clinical Nuclear Medicine 2017;42:e313-6. [DOI: 10.1097/rlu.0000000000001620] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
7 Yamaga LYI, Cunha ML, Campos Neto GC, Garcia MRT, Yang JH, Camacho CP, Wagner J, Funari MBG. 68Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with 111In-octreotide SPECT/CT and conventional imaging. Eur J Nucl Med Mol Imaging 2017;44:1695-701. [PMID: 28429044 DOI: 10.1007/s00259-017-3701-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
8 Stollberg S, Kämmerer D, Neubauer E, Schulz S, Simonitsch-Klupp I, Kiesewetter B, Raderer M, Lupp A. Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin. J Cancer Res Clin Oncol 2016;142:2239-47. [PMID: 27544389 DOI: 10.1007/s00432-016-2220-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
9 Liu D, Balkin ER, Jia F, Ruthengael VC, Smith CJ, Lewis MR. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate. Nucl Med Biol 2015;42:704-10. [PMID: 26081917 DOI: 10.1016/j.nucmedbio.2015.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
10 Jain S, Sharma P, Dhull VS, Bal C, Kumar R. Lymphoma as a second malignancy in a patient with neuroendocrine tumor: mimicking dedifferentiation on dual-tracer PET/CT with 68Ga-DOTANOC and 18F-FDG. Clin Nucl Med 2014;39:358-9. [PMID: 24217543 DOI: 10.1097/RLU.0b013e31828e98c5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
11 Mattoon JS, Bryan JN. The future of imaging in veterinary oncology: Learning from human medicine. The Veterinary Journal 2013;197:541-52. [DOI: 10.1016/j.tvjl.2013.05.022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
12 Kong FL, Ford RJ, Yang DJ. Managing lymphoma with non-FDG radiotracers: current clinical and preclinical applications. Biomed Res Int 2013;2013:626910. [PMID: 23841079 DOI: 10.1155/2013/626910] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
13 Ferone D, Pivonello R, Kwekkeboom DJ, Gatto F, Ameri P, Colao A, de Krijger RR, Minuto F, Lamberts SW, van Hagen PM. Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the in vivo visualization during somatostatin receptor scintigraphy. J Endocrinol Invest. 2012;35:528-534. [PMID: 21765239 DOI: 10.3275/7871] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
14 Apostolopoulos DJ, Papandrianos NI, Symeonidis A, Spyridonidis T, Alexiou S, Zampakis P, Savvopoulos C, Vassilakos PJ, Matsouka P. Technetium-99m depreotide imaging by single photon emission tomography/low resolution computed tomography in malignant lymphomas: comparison with gallium-67 citrate. Ann Nucl Med 2010;24:639-47. [PMID: 20799079 DOI: 10.1007/s12149-010-0405-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Saeed P, Tanck MW, Freling N, Baldeschi L, Mourits MP, Bennink RJ. Somatostatin Receptor Scintigraphy for Optic Nerve Sheath Meningiomas. Ophthalmology 2009;116:1581-6. [DOI: 10.1016/j.ophtha.2009.02.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
16 Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA. Tumor receptor imaging. J Nucl Med 2008;49 Suppl 2:149S-63S. [PMID: 18523071 DOI: 10.2967/jnumed.107.045963] [Cited by in Crossref: 117] [Cited by in F6Publishing: 120] [Article Influence: 8.4] [Reference Citation Analysis]
17 Kostakoglu L, Coleman M, Goldsmith SJ. Hodgkin’s Disease and Lymphomas. Clinical Nuclear Medicine. [DOI: 10.1007/978-3-540-28026-2_16] [Reference Citation Analysis]
18 Reske SN. FDG-PET and PET/CT in Malignant Lymphoma. In: Dresel S, editor. PET in Oncology. Berlin: Springer Berlin Heidelberg; 2008. pp. 93-107. [DOI: 10.1007/978-3-540-31203-1_8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Hematological, reticuloendothelial and lymphatic disorders. Clinical Nuclear Medicine 2006. [DOI: 10.1201/b13348-69] [Reference Citation Analysis]
20 Schillaci O. Single-Photon Emission Computed Tomography/Computed Tomography in Lung Cancer and Malignant Lymphoma. Seminars in Nuclear Medicine 2006;36:275-85. [DOI: 10.1053/j.semnuclmed.2006.05.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
21 Reske S. PET Assessment of Lymphoma: Beyond 18F-Fluorodeoxyglucose. PET Clinics 2006;1:275-81. [DOI: 10.1016/j.cpet.2006.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Ferone D. Neuroendocrine-Immune Interactions: The Role of Cortistatin/Somatostatin System. Annals of the New York Academy of Sciences 2006;1069:129-44. [DOI: 10.1196/annals.1351.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.4] [Reference Citation Analysis]
23 . Current Awareness in Hematological Oncology. Hematol Oncol 2005;23:136-43. [DOI: 10.1002/hon.731] [Reference Citation Analysis]
24 Champaneria MC, Modlin IM, Latich I, Bornschein J, Drozdov I, Kidd M. Somatostatin Analogue Therapy. In: Kaufman HL, Wadler S, Antman K, editors. Molecular Targeting in Oncology. Totowa: Humana Press; 2008. pp. 585-637. [DOI: 10.1007/978-1-59745-337-0_25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]